CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
出版年份 2015 全文链接
标题
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume 11, Issue 7, Pages 1606-1611
出版商
Informa UK Limited
发表日期
2015-05-23
DOI
10.1080/21645515.2015.1046658
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
- (2014) S Ferrero et al. LEUKEMIA
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines
- (2014) Teresa Paíno et al. PLoS One
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells
- (2012) William Matsui et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
- (2012) A. Chaidos et al. BLOOD
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model
- (2012) E Van Valckenborgh et al. LEUKEMIA
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
- (2011) N W C J van de Donk et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal Germinal Center Responses Require a Multistage T Cell:B Cell Adhesion Process Involving Integrins, SLAM-Associated Protein, and CD84
- (2010) Jennifer L. Cannons et al. IMMUNITY
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
- (2010) Jose De Salort et al. IMMUNOLOGY LETTERS
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search